Global 500

Rank
174
Previous: 173 Next: 175

Bayer

G500 2017—Bayer
A blister pack containing Femoden oral contraceptive tablets, produced by Bayer AG, sits on a pharmacy counter in this arranged photograph in London, U.K., on Thursday, Dec. 29, 2016. The rapid pace of innovation among drugmakers may continue to be overshadowed by broader investment themes, such as the switch away from defensive stocks into more cyclical industries, during 2017, according to Bloomberg Intelligence. Chris Ratcliffe—Bloomberg/Getty Images
  • Previous Rank
    165
  • Revenues ($M)
    52569
  • Revenue Percent Change
    0.3
  • Profits ($M)
    5010.6
  • Profits Percent Change
    9.9
  • Assets ($M)
    86731
  • Employees
    115170

Company Information

CEOWerner Baumann
SectorHealth Care
IndustryPharmaceuticals
HQ LocationLeverkusen, Germany
Websitewww.bayer.com
Years on Global 500 List23
Employees115,170

Key Financials (Last Fiscal Year)

Revenues ($M)$52,569
Profits ($M)$5,010.6
Assets ($M)$86,731
Total Stockholder Equity ($M)$31,990

Profit Ratios

Profit as % of Revenues9.5%
Profits as % of Assets5.8%
Profits as % of Stockholder Equity15.7%